^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tagmokitug (CHS-114)

    i
    Other names: CHS-114, SRF114, CHS114, SRF 114, CHS 114, SRF-114
    Associations

    News

    Trials
    Company:
    Coherus Oncology
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses. (PubMed, Mol Cancer Ther)
    Treatment of tumor bearing human CCR8 knock-in (huCCR8KI) mice with CHS-114 resulted in significant tumor growth inhibition (62.6%) accompanied by remodeling of the tumor immune microenvironment and enhanced differentiation of a subset of cytotoxic CD8+ T cells. Based on the promising preclinical data, we are evaluating CHS-114 in clinical trials as an investigational agent for the treatment of solid tumors with and without the anti-PD-1 antibody toripalimab (NCT05635643, NCT06657144).
    Journal
    |
    CD8 (cluster of differentiation 8) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    5ms
    CHS-114-102: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=154, Recruiting, Coherus Oncology, Inc. | N=72 --> 154
    Enrollment change
    |
    cisplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    9ms
    CHS-114-102: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Coherus Biosciences, Inc. | N=72 --> 40
    Enrollment change
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    10ms
    CHS-114-102: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Coherus Biosciences, Inc. | N=40 --> 72
    Enrollment change
    |
    cisplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    10ms
    CHS-114-102: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Coherus Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    11ms
    SRF114-101: Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=87, Recruiting, Coherus Biosciences, Inc. | N=47 --> 87
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    over1year
    A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Coherus Biosciences, Inc.
    New P1 trial
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    almost2years
    Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=47, Recruiting, Coherus Biosciences, Inc. | Phase classification: P1/2 --> P1 | N=70 --> 47
    Phase classification • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    tagmokitug (CHS-114)
    over2years
    Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma (SITC 2023)
    Molecular epidemiology studies highlight HNSCC as a tumor type with a high prevalence of CCR8+ itTregs to evaluate the anti-tumor activity of an anti-CCR8 antibody. CHS-114 (SRF114) is currently being evaluated in a Phase 1 clinical trial (NCT05635643).
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression • FOXP3 expression
    |
    tagmokitug (CHS-114)
    3years
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Surface Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    tagmokitug (CHS-114)
    3years
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Surface Oncology
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    tagmokitug (CHS-114)